LncRNA PITPNA-AS1 as a Potential Diagnostic Marker and Therapeutic Target Promotes Hepatocellular Carcinoma Progression via Modulating miR-448/ROCK1 Axis

Qingfang Wang, Qinglin Wang, Mingbo CaoFrontiers in Medicine 2021 · DOI

Abstract

Background: Long non-coding RNAs are critical to hepatocellular carcinoma (HCC) developments. LncRNA PITPNA antisense RNA 1 (PITPNA-AS1) is a new regulator in several tumors. However, the mechanism by which PITPNA-AS1 mediates the tumorigenesis of HCC remains unclear. Methods: RT-qPCR was used to detect the level of PITPNA-AS1 in HCC specimens and cells. The biological functions of PITPNA-AS1 were explored by several functional experiments in vivo and in vitro. The binding relationship among PITPNA-AS1, miR-448 and ROCK1 were studied by Luciferase assay and pull-down assays. Results: We found that PITPNA-AS1 expressions were distinctly upregulated in both HCC specimens and cell lines. High PITPNA-AS1 levels were an unfavorable biomarker for patients with HCC. Functionally, knockdown of PITPNA-AS1 suppressed the proliferation, migration and invasion of HCC cells. Mechanistically, PITPNA-AS1 functioned as competing endogenous RNA to increase ROCK1 expressions via sponging miR-448. Conclusion: The newly identified PITPNA-AS/miR-448/ROCK1 axis promoted the oncogenicity of HCC cells. This novel axis is likely to be a promising HCC therapeutic aim.

Introduction

Hepatocellular Carcinoma (HCC) remains the second leading cause of cancer-related mortality worldwide. Despite advancements in surgical techniques and diagnostic tools, long-term survival is often compromised by high rates of recurrence and metastasis, which can reach 45–65% within five years. Recent research has pivoted toward the "dark matter" of the genome—non-coding RNAs—to uncover new regulatory mechanisms. Long non-coding RNAs (lncRNAs), while not protein-coding, are pivotal regulators of gene expression. PITPNA-AS1 has been implicated in other malignancies, but its role in HCC progression and its underlying molecular axis remained largely unexplored until this study.

Materials and Methods

The researchers employed a comprehensive multi-disciplinary strategy:

  • Expression Profiling: RT-qPCR quantified PITPNA-AS1 levels in 93 pairs of HCC and adjacent normal tissues, alongside various liver cancer cell lines (Hep3B, HepG2, SMMC-7721, HCCLM3) and a normal control (L02).
  • Functional Characterization: Short hairpin RNA (shRNA) was used to knock down PITPNA-AS1. Subsequent assays measured cell proliferation (CCK-8, colony formation), migration (wound healing), and invasion (Transwell).
  • Mechanistic Validation: Luciferase reporter and RNA pull-down assays were conducted to confirm the physical interaction between PITPNA-AS1, miR-448, and ROCK1.
  • In Vivo Models: Xenograft studies in nude mice evaluated the impact of PITPNA-AS1 silencing on tumor growth over a 28-day period.

Results

PITPNA-AS1 is Significantly Upregulated in HCC

Analysis of the clinical cohort revealed that PITPNA-AS1 expression is markedly higher in tumor tissues compared to matched normal tissues. This finding was consistent across multiple bioinformatics datasets, including TCGA.

Relative expression of PITPNA-AS1 in HCC tumor tissues vs. adjacent normal tissues (n=93).

Clinical Significance and Survival Outcomes

High expression of PITPNA-AS1 was statistically correlated with larger tumor size, advanced clinical stages (III-IV), and poor prognosis. Kaplan-Meier analysis demonstrated that patients with high PITPNA-AS1 levels had significantly shorter overall survival (OS) and disease-free survival (DFS).

Kaplan-Meier analysis of overall survival (OS) based on PITPNA-AS1 expression levels.

The PITPNA-AS1/miR-448/ROCK1 Axis

The study identified PITPNA-AS1 as a competing endogenous RNA (ceRNA). In healthy liver cells, miR-448 typically suppresses the expression of the oncogenic protein ROCK1. However, in HCC, overexpressed PITPNA-AS1 acts as a "molecular sponge," sequestering miR-448. This sequestration prevents miR-448 from binding to ROCK1 mRNA, leading to increased ROCK1 levels and subsequent promotion of tumor growth, migration, and invasion.

Discussion and Conclusion

This research successfully maps the PITPNA-AS1/miR-448/ROCK1 axis as a driver of HCC progression. The diagnostic potential of PITPNA-AS1 is supported by an ROC curve AUC of 0.7810. While the study provides strong evidence for this pathway, future work should involve larger multi-center cohorts and explore the therapeutic delivery of anti-sense oligonucleotides to target this lncRNA in clinical settings. In conclusion, PITPNA-AS1 represents a promising biomarker and a potential therapeutic target for improving outcomes in patients with HCC.

Summary updated

Abstract

<b>Background:</b> Long non-coding RNAs are critical to hepatocellular carcinoma (HCC) developments. LncRNA PITPNA antisense RNA 1 (PITPNA-AS1) is a new regulator in several tumors. However, the mechanism by which PITPNA-AS1 mediates the tumorigenesis of HCC remains unclear. <b>Methods:</b> RT-qPCR was used to detect the level of PITPNA-AS1 in HCC specimens and cells. The biological functions of PITPNA-AS1 were explored by several functional experiments <i>in vivo</i> and <i>in vitro</i>. The binding relationship among PITPNA-AS1, miR-448 and ROCK1 were studied by Luciferase assay and pull-down assays. <b>Results:</b> We found that PITPNA-AS1 expressions were distinctly upregulated in both HCC specimens and cell lines. High PITPNA-AS1 levels were an unfavorable biomarker for patients with HCC. Functionally, knockdown of PITPNA-AS1 suppressed the proliferation, migration and invasion of HCC cells. Mechanistically, PITPNA-AS1 functioned as competing endogenous RNA to increase ROCK1 expressions via sponging miR-448. <b>Conclusion:</b> The newly identified PITPNA-AS/miR-448/ROCK1 axis promoted the oncogenicity of HCC cells. This novel axis is likely to be a promising HCC therapeutic aim.
BibTeX
@inproceedings{wang2021lncrna,
  author = {Qingfang Wang and Qinglin Wang and Mingbo Cao},
  title = {{LncRNA PITPNA-AS1 as a Potential Diagnostic Marker and Therapeutic Target Promotes Hepatocellular Carcinoma Progression via Modulating miR-448/ROCK1 Axis}},
  booktitle = {Frontiers in Medicine},
  year = {2021},
  doi = {10.3389/fmed.2021.668787},
}
Figure